Anti-Monkey/Human CD40L/CD154 Antibody (5C8)
Based on 1 publication(s) in Google Scholar
Anti-Monkey/Human CD40L/CD154 Antibody (5C8) is a mouse-derived IgG2a type antibody inhibitor, targeting to monkey/human CD40L/CD154. Anti-Monkey/Human CD40L/CD154 Antibody (5C8) blocks the interactionbetween CD154 and CD40. Anti-Monkey/Human CD40L/CD154 Antibody (5C8) can be used for the researches of inflammation and immunology, such as colitis and transplant.
For research use only. We do not sell to patients.
- Purity: 95.00%
- Molecular Weight:150 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Anti-Monkey/Human CD40L/CD154 Antibody (5C8)
More
Biological Activity
Mouse IgG2a kappa
Human/Monkey
CD40L/CD154
Anti-Monkey/Human CD40L/CD154 Antibody (5C8) (0.01-100 μg/mL) inhibits rhesus mixed lymphocyte reactions[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Anti-Monkey/Human CD40L/CD154 Antibody (5C8) (250 μg/mouse, i.p., twice a week for 8 weeks) prevents the onset and severity of experimental colitis in CD45RBhigh CD4+ T cell reconstitution mice models[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Renal allotransplant mice models[1]
-
Dosage:20 mg/kg
-
Administration:Intravenously injection, every other day beginning on the day of surgery and continuing for 14 postoperative days
-
Result:Experienced extended rejection-free survival and rejected between 95 and 100 days posttransplant.
Returned to normal graft function when re-treated with 7 doses of 5C8 (20 mg/kg).
-
Animal Model:CD45RBhigh CD4+ T cell reconstitution mice models[2]
-
Dosage:250 μg/mouse
-
Administration:Intraperitoneally injection, twice a week for 8 weeks
-
Result:Did not exhibit any signs of colitis, with gradual increase of body weight and absence of diarrhea and no detectable pathological changes.
Resulted in a significant reduction of splenomegaly and of the lymphocyte infiltration in the spleen, the liver and lymphoid nodes.
Showed a low frequency of CD4+ T cells, F4/801 macrophages, and CD54+ cells.
-
Animal Model:CD45RBhigh CD4+ T cell reconstitution mice models[2]
-
Dosage:250 μg/mouse
-
Administration:Intraperitoneally injection, twice a weekfor from 5 to 8 week
-
Result:Significantly diminished granulomatous inflammation, leukocyte infiltration, and epithelial hyperplasia.
Significantly decreased histological scores in the colonic sections.
Reduced CD4+ T cells and IL-2 and IFN-γ production.
Decreased mRNA levels of cytokinesas well as CD40, CD40L and IL-4, IL-5, and IL-10.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
in vitro blocking of CD40/CD40L signaling; in vivo blocking of CD40/CD40L signaling; Immunoprecipi
-
Flow cytometric analysis of 1X106 500 ng/mL anti-CD3 and 500 ng/mL ant-CD28 co-stimulated Jurkat cells(24h) with Anti-Monkey/Human CD40L/CD154 Antibody (5C8) (HY-P990133, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Mouse IgG H&L (HY-P8005) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Mouse IgG2a kappa (HY-P99978, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
Appearance Liquid
-
Molecular Weight 150 kDa
-
Color Colorless to light yellow
-
SMILES
[Anti-Monkey/Human CD40L/CD154 Antibody (5C8)]
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Microcirculation
Aggregation of Platelets and Human EGFR Mutant Lung Adenocarcinoma Cells Under Flow Is Governed by Shear Accumulation. [Abstract]2026 Jan;33(1):e70047. PMID: 41474549
Purity & Documentation
-
Data Sheet (263 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Kirk AD, et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci U S A. 1997 Aug 5;94(16):8789-94. [Content Brief]
[2]. Liu Z, et al. Prevention of experimental colitis in SCID mice reconstituted with CD45RBhigh CD4+ T cells by blocking the CD40-CD154 interactions. J Immunol. 2000 Jun 1;164(11):6005-14. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anti-Monkey/Human CD40L/CD154 Antibody (5C8) Related Classifications
HY-P990133 Related Classifications
Powered by Bioz